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Abstract 
Myelinating cells wrap axons with multilayered myelin sheaths for rapid impulse propagation. 
Dysfunctions of oligodendrocytes or Schwann cells are often associated with 
neuroinflammation, as observed in animal models of leukodystrophies and peripheral 
neuropathies, respectively. The neuroinflammatory response modulates the pathological 
changes, including demyelination and axonal injury, but also remyelination and repair. Here 
we discuss different immune mechanisms as well as factors released or exposed by 
myelinating glia in disease conditions. The spectrum of inflammatory mediators varies with 
different myelin disorders and has a major impact on the beneficial or detrimental role of 
immune cells in nervous system integrity. 
Keywords: leukodystrophy; microglia/macrophages; myelin; neuroinflammation; 
neuropathy; T cells. 
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Introduction 
Myelinated axons enable rapid propagation of nerve impulses in the vertebrate nervous 
systems. Axonal ensheathment results from the spiral wrapping and compaction of a highly 
specialized glial plasma membrane. Compared to other cellular membrane, myelin is more 
concentrated in lipid whose composition is distinct with a higher content of cholesterol and 
sphingolipids (Norton and Cammer, 1984). Improved proteomic techniques resulted in the 
discovery of a much larger myelin proteome than originally thought, with more than 1200 
myelin-associated proteins in the central nervous system (CNS) and about 500 different 
proteins in the peripheral nervous system (PNS) (de Monasterio-Schrader et al., 2012). Far 
fewer proteins, are structural components of compacted myelin, such as myelin basic protein 
(MBP) and proteolipid protein (PLP/DM20) in the CNS, or the peripheral myelin protein 
22 (PMP22) and myelin protein zero (MPZ or P0) in the PNS. In the so-called  
‘non-compacted’ myelin compartment, which may actually serve as a channel system for the 
maintenance of axon-glia interactions (Nave, 2010), other myelin proteins ensure transport, 
signaling and metabolic functions. 
The more frequent inherited myelin diseases have been associated with copy number 
variations or mutations of genes encoding myelin structural proteins like in Pelizaeus 
Merzbacher disease (PMD) and Charcot Marie tooth disease (CMT). Indeed, in animal 
models of these diseases, overexpression and mutation of myelin membrane proteins often 
leads to endoplasmic reticulum stress, dysmyelination and demyelination, and axonal loss, 
invariably coupled to a neuroinflammatory response. Neuroinflammation comprises the 
activation of microglia/macrophages and astrocytes, and in more severe cases the infiltration 
of lymphocytes (B, T and NK cells). Microglia and the endoneurial macrophages are resident 
immune cells of the CNS and the PNS respectively. In their role as sentinels, they keep the 
neural tissue under surveillance. This is achieved by integrating numerous ligand-receptor 
signaling events that ultimately inform the resident microglia/macrophages about the health 
status of the neighboring neural parenchyma. Well studied signaling systems include the 
ligand/receptor pairs CD200/CD200R, CD47/SIRPα, CX3CL1/CX3CR1 and CD22/CD45 
(Hanisch, 2013). Demyelination, which is often accompanied by axonopathies activates 
resident microglia/macrophages and, in some cases, recruits inflammatory myeloid cells 
(monocyte, neutrophils) and lymphocytes from the periphery. All these cells can adopt 
different phenotypes for specialized functions, such as phagocytic activity, cytotoxicity,  
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pro-inflammatory, anti-inflammatory cytokine release, and the support of tissue repair. 
However, their overall impact as a mixed population of immune cells on the course of disease 
is difficult to predict. Nevertheless, ‘neuroinflammation’ is often viewed as a response that is 
predominantly detrimental in myelin diseases of CNS and PNS, not only in multiples sclerosis 
(MS), but also in leukodystrophies and neuropathies. Indeed, immunosuppressive treatments 
often relieve clinical symptoms. Moreover, inflammatory cells often co-localize with sites of 
local demyelination and axonal injury, as studied in detail in mice that model 
leukodystrophies and neuropathies (Edgar et al., 2010; Ip et al., 2006b). Thus in some 
conditions, limiting neuroinflammation might be a promising therapeutic strategy. 
Notwithstanding known side effects of immunosuppressive drugs, a better understanding of 
inflammatory mediators in neurodegenereative diseases might help identify new targets that 
are advantageous compared to known immunosuppressive drugs. 
Demyelination can be a cause or a consequence of neuroinflammation 
In contrast to ‘dysmyelination’, which denotes a developmental perturbation of myelinating 
glia, the term ‘demyelination’ refers to the progressive degeneration and degradation of 
previously intact myelin, which can have very different causes. The best known and clinically 
most important is multiple sclerosis (MS), a severe neurological disease, in which 
demyelination is driven, if not caused, by autoreactive T cells and B cells that target 
oligodendrocytes and myelin antigens (Brennan et al., 2011; Derfuss et al., 2009). Another 
example of a consequential (secondary) demyelination caused by (primary) 
neuroinflammation is Guillain-Barré syndrome (GBS), in which the underlying mechanisms 
are less complex and better understood (Table 1). In some GBS patients, a rather sudden 
autoimmune response is directed against an antigenic epitope that is common to a specific 
ganglioside found in peripheral myelin and also in the cell wall of a gastroenteric pathogen, 
Campylobacter jejuni. Here, the underlying cause of demyelination, triggered by 
autoaggressive antibodies after an acute infection, is the ‘epitope-mimicry’ and late response 
against a self antigen that is shared with the foreign pathogen. It has been suspected that 
epitope-mimicry is also involved in multiple sclerosis (MS), although the responsible  
auto-antigen in MS patients is not known. The focus of this review, however, is on the 
opposite scenario, with demyelination and axonal degeneration being the (primary) cause of 
(secondary) neuroinflammation (Table 1). 
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Neuroinflammation of peripheral nerves and white matter tracts is initiated when myelinating 
cells are lost due to apoptosis and/or necrosis and axons and myelin sheaths degenerate, e.g. 
after spinal cord injury and peripheral nerve lesion or after ischemic insult. Also, genetic 
defects that perturb oligodendrocyte or Schwann cell function, myelin architecture, or the 
homeostasis of axon-myelin units can be ‘sensed’ by resident immune cells that respond by 
becoming activated and possibily recruiting lymphocytes. In the next sections, we summarize 
the current knowledge of critical signaling molecules, such as DAMPs (‘damage- or  
danger-associated molecular pattern molecules’) and inflammatory mediators, which are 
exposed to immune cells in the context of demyelinating disease and that shape the overall 
neuroimmune response. 
Oligodendroglial death and clearance of degenerating myelin 
membranes 
Trauma or ischemia of the CNS can cause a massive loss of oligodendrocytes by apoptosis 
and necrosis. This is followed by a rapid influx of hematogenous inflammatory cells, i.e. 
neutrophils and monocytes/macrophages, to the lesion site and the activation of resident 
microglial cells (David and Kroner, 2011). It is still unresolved whether these cells are 
ultimately beneficial for CNS integrity or whether they cause a second wave of tissue damage 
due to their high phagocytic activity. In vitro studies have shed light on the molecular 
machinery orchestrating the disposal of myelin debris when oligodendrocytes die by 
apoptosis or necrosis. An important mechanism is the activation of the complement system 
with proteins that bind myelin debris and promote phagocytosis by microglia/macrophages 
via the complement receptor CR3/MAC-1 (Bruck and Friede, 1991; Reichert and Rotshenker, 
2003). By studying microglial cultures to which exogenous myelin vesicle were added and in 
which CR3/MAC-1-blocking antibodies and complement were present, it was shown that 
about 80% of the myelin clearance depends on CR3/MAC-1 signaling. The remaining 
CR3/MAC-1-independent myelin phagocytosis could be attributed, at least in part, to the 
scavenger receptors AI/II (SRA-I/II), which have a high affinity for oxidized lipids  
(Reichert and Rotshenker, 2003). Also after sciatic nerve injury in the PNS, CR3/MAC-1 and 
SRA-I/II are the dominant receptors on macrophages responsible for the first phase of rapid 
myelin debris clearance that occurs within 6 days after crush. Here, the late phase of myelin 
clearance was shown to be more dependent on the binding of myelin-specific IgG and IgM 
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antibodies, which are recognized by the immune cell receptor (FcRγ) on macrophages. This 
late phase of myelin phagocytosis is crucial to support subsequent nerve repair, as evidenced 
by delayed axonal regeneration of crushed sciatic nerves in JHD mice, a strain that cannot 
secrete antibodies (Vargas et al., 2010). Recently, it was demonstrated that myelin-derived 
membrane vesicles are taken up by microglia/macrophages via endocytosis of the low-density 
lipoprotein receptor-related protein (LRP1). Pull-down assays performed with LRP1 fusion 
proteins (containing the main ligand-binding domain) and solubilized myelin membrane 
vesicles have identified two myelin proteins, MBP and PLP, as ‘ligands’ for the human LRP1, 
suggesting that they were captured by their association with lipids (Fernandez-Castaneda  
et al., 2013). This list of myelin-specific ‘ligands’ comprises also proteins of non-compact 
myelin, such as myelin associated glycoprotein (MAG), 2/ 3/-cyclic-nucleotide  
3/-phosphodiesterase (CNP), and septins 2, 7 and 8, presumably exposed on apoptotic/necrotic 
myelinating cells. Many others receptors have been implicated in the engulfment of necrotic 
and apoptotic cells (Sierra et al., 2013), but their relevance to demyelination is unclear. 
Cuprizone-induced demyelination constitutes an animal model in which the acute loss of 
oligodendrocytes by apoptosis is triggered in only a few vulnerable myelinated tracts, 
primarily the corpus callosum. It is achieved by feeding adult C57bl/6 mice for about 
2.5 weeks with a diet containing 0.2% cuprizone, a toxic copper chelator, which produces a 
loss of subcortical white matter that overlaps with robust microgliosis as a sign of myelin 
clearance (Voss et al., 2012). Release by dying oligodendrocytes of cytosolic DAMPs, which 
are ligands for Toll-like receptors or purinergic P2X receptors (DNA, RNA, heat shock 
proteins, ATP) (Pineau and Lacroix, 2009), are likely to be detected by 
microglia/macrophages and astrocytes. Indeed, it was recently reported that myelin stripping 
in the corpus callosum of mice fed with curprizone is stalled when proliferating (reactive) 
astrocytes were specifically killed by transgenic toxin expression (Skripuletz et al., 2012). 
This could indicate that astrogliosis is essential for microglial phagocytosis (Figure 1). In fact, 
expression of CXCL10 (a key pro-inflammatory chemokine in astrocytes, which serves to 
recruit inflammatory microglia/macrophages) was lower in mice in which astrogliosis was 
prevented. This model is supported by the observation that administration of laquinimod  
(an immunomodulatory drug interfering with the pro-inflammatory NF-κB pathway in 
astrocytes) in cuprizone fed mice decreases the release of CXCL10 and other cytokines, and 
also the extent of axon loss and demyelination (Bruck et al., 2012).  
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Detection of abnormal oligodendrocytes, stripping of compact myelin and clearance of myelin 
debris could also be initiated by microglia/macrophages upon recognition of an ‘eat-me’ 
signal. A well-known example is phosphatidylserine (PS) when translocated to the outer 
leaflet of a plama membrane and binding the soluble Gas6 protein (for ‘growth arrest-specific 
gene 6’) (Figure 1). The resulting PS-Gas6 cluster is a ligand for a triad of protein-tyrosine 
kinase receptors, termed TAM-receptors (Tyro3, Axl, Mer), which are expressed on 
microglia/macrophages and trigger phagocytosis (Binder and Kilpatrick, 2009). Genetically 
inactivating the Axl receptor, a protein upregulated on microglia during cuprizone treatment, 
prevents microgliosis and delays the generation of myelin debris and its clearance in mutant 
mice (Hoehn et al., 2008). Furthermore, the spontaneous remyelination following the switch 
to normal chow is slightly delayed when Axl is absent, and there is a significant increase of 
autophagosome-like vesicles in dystrophic axons. Some of these histopathological defects, 
when appearing in wild-type mice treated with cuprizone, can be diminished by infusion of 
recombinant Gas6 (rhGas6) directly into the brain, which promotes the clearance of myelin 
debris (Tsiperson et al., 2010). In cuprizone fed mice, the receptor TREM-2b  
('triggering receptor expressed on myeloid cells-2b') is the most abundant phagocytosis 
receptor on microglia cells, however its myelin-associated physiological ligand remains 
unknown (Voss et al., 2012). It is tempting to speculate that targeting these molecules opens a 
possibility to accelerate phagocytosis in diseases in which protracted myelin clearance is a 
burden on axon survival (Figure 1). 
The molecular machinery underlying phagocytosis of myelin debris by 
microglia/macrophages has been studied in vitro and in cuprizone-fed mice. However, 
validation of these mechanisms in other in vivo models with demyelination is important to 
understand the role of neuroinflammation, a known bystander effect of inherited myelin 
diseases. This could be done in mouse models of human myelin diseases, such as Plp1 
overexpressing (for PMD) or MPZ heterozygous mice (for CMT1B) that reveal a substantial 
degree of secondary inflammatory response (Ip et al., 2006a,b). 
Leukodystrophies and neuropathies caused by perturbed expression of 
myelin protein genes 
A unique cause of inherited myelin diseases is the duplication of genes that encode polytopic 
myelin membrane proteins. For instance, duplication of the X chromosome-linked proteolipid 
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protein locus (PLP1) accounts for 60-70% of patients with PMD. Similar to point mutations 
in this gene, PLP1 overexpression in PMD causes CNS dysmyelination and demyelination, 
leading to developmental delays with nystagmus, ataxia, spasticity and progressive axonal 
loss (Woodward, 2008).  
Duplication of peripheral myelin protein 22 (PMP22) gene underlies the most frequent form 
(about 60%) of inherited demyelinating neuropathy, Charcot-Marie Tooth disease type 1A 
(CMT1A). CMT1A patients develop distally pronounced sensory loss and progressive muscle 
weaknesses, leading to loss of tendon reflexes and foot deformities (Wrabetz et al., 2004). 
While consequences of the neuroinflammatory response on the progression of pathologies 
have not yet been systematically investigated in human PMD and CMT1A patients, 
corresponding rodent models of these diseases have demonstrated an important effect of 
microglia/macrophages and lymphocytes in disease expression.  
Duplications of the X-linked PLP1 gene have been modeled in transgenic mice carrying 
autosomal Plp1 transgenes (Readhead et al, 1994). Two mouse lines (Plp66/66 and Plp72/72), 
with 7 and 3 copies of a Plp1 cosmid per haploid genome, have been most widely studied. 
The mouse line Plp72/72, which overexpress Plp1 about 1.6-fold, are bona fide PMD models 
with ataxia, tremors, and seizures. In all transgenics the degree of 
dysmyelination/demyelination is proportional to Plp1 gene dosage (Readhead et al., 1994). In 
the CNS of 12 months-old Plp66/+ mice, corpus callosum, cerebellum, spinal cord, and optic 
nerves are filled with numerous (CD11b+) leukocytes (Ip et al., 2006a). Moreover, CD11b+ 
and CD45+ inflammatory cells are detected in the optic nerve where active demyelination is 
associated with axonopathy (Edgar et al., 2010; Ip et al., 2006a). These PMD models have 
enabled the identification of inflammatory cells receptors and cytokines relevant for the 
pathology progression. For example, in Plp66/+ mice, Ip et al. demonstrated that ablation of the 
gene for sialoadhesin (Sn/CD169), a macrophage-restricted adhesion molecule and receptor 
for sialylated glycolipids, tempers the secondary neuroinflammation as well as the extent of 
demyelination and axonal degeneration in the optic nerve (Ip et al., 2007). A similar 
modulatory function can be seen in the peripheral nervous system. Here, MPZ is the most 
abundant membrane protein of myelin synthesized by Schwann cells. Mpz heterozygous mice 
develop a late onset neuropathy with secondary infiltration of macrophages and active 
demyelination, beginning at 4 months of age. When these mutants (which model CMT1B) 
additionally lack expression of Sn/CD169 in macrophages, the demyelinating histopathology 
is significantly attenuated (Kobsar et al., 2006). 
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Apparently, Sn/CD169 and its myelin-associated ligands (i.e. sialated glycolipids) constitute a 
signaling pathway common to CNS and PNS that controls myelin phagocytosis. For 
heterozygous Mpz mice, it has been shown that cytokine-like macrophage-colony stimulating 
factor (M-CSF) and monocyte chemoattractant protein-1 (MCP-1) are released by mutant 
Schwann cells, which are then instrumental in stimulating the proliferation and recruitment, 
respectively, of resident macrophages. Lowering the release of these cytokines substantially 
reduces the extent of PNS demyelination (Martini et al., 2008) (Figure 2). 
The normal localization of CNS microglia or PNS macrophages in myelinated nervous tracts 
allows these cells to be the first to respond to myelin-derived ‘eat-me’ signals and to initiate 
myelin fragmentation and later the clearance of myelin debris. Interestingly, the pathological 
demyelination observed in these PMD and CMT1B models is enhanced by the adaptive 
immune system, i.e. secondarily invading lymphocytes. This was experimentally shown by 
crossbreeding either Plp66/+ transgenic or Mpz heterozygous mice with recombinase RAG-1 
deficient mice, which lack functional B and T cells. This led in both lines to a reduction in the 
degree of demyelination in the optic and peripheral nerves, and allowed more axons to survive 
(Ip et al., 2006a; 2006b). It is therefore surprising that a similar lack of B and T cells did not 
affect peripheral demyelination in a Pmp22 transgenic mouse model of CMT1A  
(Kohl et al., 2010). We hypothesize that the secondary immune response differs between 
mouse models as a function of the underlying myelin defect. In Mpz heterozygous mice, a 
relative lack of the major adhesion protein of myelin is likely to result in local delamination 
(Martini et al., 1995), as shown in detail for a cholesterol-deficient mutant with a similar 
reduction of MPZ in myelin (Saher et al., 2009). Unstable myelin may lead to membrane 
shedding, phagocytosis and antigen presentation to autoimmune T cells, all of which might 
not be a feature of Pmp22 transgenic mice. We also note that Mpz heterozygous mice harbor 
T cells that can be stimulated by MBP (Schmid et al., 2000), suggestive of prior epitope 
spreading. 
CD8+ T cells constitute the most abundant lymphocyte population in the brains of Plp1 
transgenic mice (line Plp66/+) and are clonally expanded in some animals (Leder et al., 2007). 
The presence of CD8+ cells raises the question whether they participate directly in CNS 
demyelination by inducing oligodendrocytes apoptosis by T cell-mediated cytotoxicity.  
CD8+ cells invading the optic nerve have a preferential localization at the 
paranodal/juxtaparanodal region, a likely bottle neck for retrograde axonal transport  
(Ip et al., 2012). The antigen specificity of these CD8+ cells from mutant brains is unknown, 
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and splenocytes from these mice do not proliferate in response to predicted MHC-I peptides 
synthesized in vitro (Leder et al., 2007). It is still unclear how lymphocytes in the lymphoid 
organs are stimulated when oligodendrocytes are dysfunctional, and how they reach the CNS. 
It is possible that a small number of autoreactive T-cells recruits a second wave of 
lymphocytes through a perturbed blood brain barrier. That could be tested by cross-breeding 
Plp1 transgenic with CCR6-deficient mice, in which the primary access of autoimmune  
T cells to the brain via the choroid plexus is blocked (Reboldi et al., 2009). Similarly,  
cross-breeding Plp1 transgenics with β2m KO mice (in which the lack of β2-microglobulin 
prevents the assembly of functional MHC class I) could help decide whether it is MHC class 
I-dependant mechanisms of infiltrating CD8+ cells (Linker et al., 2005) that contribute to 
demyelination and axonopathy in this model. 
Surprisingly, massive killing of transgenic oligodendrocytes with diphtheria toxin causes 
widespread demyelination and microglia/macrophage activation, but is not sufficient to attract 
a significant number of T cells (Locatelli et al., 2012; Pohl et al., 2011; Traka et al., 2010). 
Also in others models of induced oligodendroglial apoptosis (i.e. cuprizone), the recruitment 
of T cell is marginal. This contrasts with the phenotype of previously described mutants, in 
which various genetic perturbations of oligodendrocyte function (Plp1 transgenic, Pex5 
conditional-KO mice, see below) causes significant lymphocyte invasion concomitant with 
demyelination and low level of oligodendroglial apoptosis. This suggest that it requires live 
(but injured) oligodendrocytes to trigger T cell infiltration. Alternatively, there are underlying 
signals from degenerating neurons and axons that cause T cell infiltration, which are therefore 
due to secondary axonal loss in myelin mutant mice. Among different models, the variability 
of axonal involvement differs and perturbations of myelin function (in Plp1 trangenic mice) 
may be more detrimental to axon survival than transient demyelination induced by diphtheria 
toxin (Locatelli et al., 2012; Pohl et al., 2011; Traka et al., 2010). We note that, in contrast to 
oligodendrocytes, the genetic ablation of adult hippocampal neurons in transgenic mice with 
an inducible diphteria toxin gene causes significant infiltration of T cells (Agarwal et al., 
2012).  
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Neuroinflammation of white matter in mouse models of peroxisomal 
and lipid storage disorders 
Demyelinating disease can occur as a result of dysfunction of organelles, such as peroxisomes 
and lysosomes, which play a major role in lipid metabolism of myelinating cells. Lipids make 
up 70-75% of the dry weight of purified myelin membranes. Some of these lipids and their 
derivatives are viewed as potential stimulators of immune responses in leukodystrophies 
characterized by an abnormal myelin lipid turnover. For example, the X-linked recessive 
adrenoleukodystrophy (X-ALD) is a demyelinating disorder caused by a peroxisomal 
dysfunction, and has an incidence of 1 in 21 000 male newborns (Bezman et al., 2001). In 
these patients, the ABCD1 gene, which encodes a membraneous transporter that shuttles very 
long chain fatty acids (VLCFA) into the peroxisomal lumen for their degradation by  
β-oxidation, is mutated. In severe cases, male patients are affected at childhood by the 
cerebral form of X-ALD, which produces a rapid progressive demyelination of subcortical 
white matter (Moser et al., 2007). Functional deficits in this disease, starting between 4 and 
8 years of age, are then caused by focal myelin loss, axonal degeneration, and recruitment of 
inflammatory cells to demyelinated areas, typically in the periventricular white matter of the 
parieto-occipital cortex (Eichler and Van Haren, 2007).  
In patients with metachromatic leukodystrophy (MLD), the lysosomal degradation of 
sulfatide is impaired due to mutation of the arylsulfatase A gene (Asa1). Sulfatide  
(the sulfated form of galactocerebroside) is a frequent lipid of the myelin sheath but 
accumulates also in other neural cells. MLD has an incidence 1 in 40 000 births and manifests 
with ataxia and hypotonia, whereas its onset can vary widely between childhood to adulthood. 
With increasing age, there is deterioration of hearing, vision, speech and cognitive 
capabilities, and also peripheral nerves become involved. With respect to neuroinflammation, 
activated perivascular microglia/macrophages are a salient feature of demyelinated lesions in 
MLD (Eichler and Van Haren, 2007). Progression of disease in X-ALD (or MLD) can be 
halted when allogeneic hematopoietic cell transplantation or autologous hematopoietic stem 
cell gene therapy are performed before the appearance of severe neurologic deficits  
(Biffi et al., 2011; Cartier et al., 2009). The benefit of this therapy has been accredited to the 
invasion of donor-derived microglia/macrophages that have normal peroxisomal  
(and lysosomal) functions. 
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So far, mutations in Abcd1 and Asa1 genes in mice have failed to provide clinical models of 
X-ALD and MLD diseases. To obtain a phenocopy of X-ALD in mice, including CNS 
demyelination and the secondary inflammatory response, a new model has been created by 
targeting the gene for the peroxisomal biogenesis factor peroxin-5 (Pex5) selectively in 
oligodendrocytes (Pex5flox/flox*CNP-Cre/+ mice), causing the loss of virtually all 
oligodendroglial peroxisomal functions (Kassmann et al., 2007). This mouse is viable and is 
well myelinated until the sixth month of life when hindlimb ataxia becomes obvious. With 
further ageing, clinical dysfunctions worsen (hunchback, hindlimb paresis, tremor, paralysis) 
and culminate in terminal breathing difficulties at about one year. Magnetic resonance 
imaging revealed that sub-cortical myelinated fiber tracts are the first to deteriorate  
(corpus callosum, hippocampal fimbria, anterior commissure) with minimal impact in the 
caudal brain. Elevated VLCFA concentration in the brain and locomotor dysfunctions 
correlate with neuroinflammation, which is dominated by activated microglia/macrophages 
and infiltrating CD8+ T-cells into areas of demyelination and axonal loss. This model will 
allow us to determine the cause of neuroinflammation, the property of infiltrating B and 
T cells and to genetically uncouple inflammation and demyelination. Essentially the same 
phenotype is seen in Nestin-Cre*Pex5 mutant mice that lack peroxisomes from virtually all 
neurons and macroglial cells (Bottelbergs et al., 2012). This suggests that the key  
anti-inflammatory function in the brain is provided by oligodendroglial peroxisomes, which 
are also associated with the myelin sheath (Kassmann et al., 2011). 
Why secondary neuroinflammation is stronger in this compared to other mouse models of 
human leukodystrophies is unknown. It is possible that a pro-inflammatory milieu is caused 
by the accumulation of eicosanoids (prostaglandins and leukotrienes) that are normally 
degraded by peroxisomal β-oxidation (Kassmann and Nave, 2008). However, the specific 
blockage of only peroxisomal β-oxidation in oligodendrocytes (Cnp1-Cre*Mfp2flox/flox) does 
not cause an equivalent degree of inflammatory demyelination (Verheijden et al., 2013). 
Another peroxisomal mutant (Gnpat-/-) that completely lacks the ability to synthesize ether 
lipids (plasmalogens), suggests that loss of this radical scavenger is not sufficient to trigger 
inflammation. 
Bottelbergs et al. have found, in Nestin-Cre*Pex5flox/flox mouse, a strong upregulation of both 
complement factor C1q and TNF-α in the corpus collosum prior to any sign of inflammatory 
demyelination (Bottelbergs et al., 2012). The soluble C1q protein is part of the complement 
system. When C1q binds cellular membranes, a cascade of reactions with the activation of 
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proteases is initiated that results in the deposition of molecules that mark target cells and 
facilitiate their engulfment by phagocytes via the complement receptor CR3  
(Galvan et al., 2012). Immunostainings have revealed reactive microglia associated with C1q 
deposits on abnormal lipid rafts in a cerebellar mouse mutant that lacks ganglioside 
production (Ohmi et al., 2011). Thus, when exposed to abnormal myelin, C1q binding could 
indicate an altered composition of these ganglioside-rich (sialic acid-containing glycolipids) 
raft-like microdomains. Indeed, the histopathologic features of neuroinflammation were 
ameliorated when an additional mutation affecting complement factor synthesis was included 
(Ohmi et al., 2009). Since peroxisomes are essential for myelin lipid turnover, it would be 
important to know whether peroxisomal mouse mutants harbor myelin lipid rafts that are 
altered in composition and associated with C1q-mediated complement factor as a cause of 
neuroinflammation and demyelination (Figure 2). This mechanism might not be specific to  
X-ALD mouse models. When the myelin membrane PLP is overexpressed in the CNS of 
mice, PLP accumulates in the endosomal/lysosomal compartment of oligodendrocytes. Due to 
its high affinity to cholesterol, this accumulation of PLP in the endosomal/lysosomal 
compartment deprives oligodendrocytes from free cholesterol required for normal myelination 
(Simons et al., 2002). Sequestration of free cholesterol can in turn alter the composition of 
myelin lipid rafts, which are normally rich in cholesterol. The deposition of C1q on 
biochemically abnormal myelin sheaths could cause the secondary activation of immune cells, 
and by creating a vicious cycle further perturbing oligodendrocyte function. In support of this 
hypothesis, a diet supplemented in cholesterol significantly dampens neuroinflammation in 
Plp1 overexpressing mice (line Plp72/72), thereby improving CNS myelination and 
ameliorating clinical symptoms in this model of PMD (Saher et al., 2012). 
To experimentally study abnormal sulfatide storage in the brain, a mild clinical model of 
MLD was created in mice by combining the genetic targeting of the Asa1 gene with sulfatide 
overproduction in a line of PLP-Gal3st1 transgenics (Ramakrishnan et al., 2007). These mice 
show a clasping reflex of their hindlimbs at about 16 months of age and develop paralysis 
later. Abnormal (alcianophilic) lipid inclusion bodies were detected in microglia/macrophages 
of the spinal cord white matter, and in optic nerve and corpus callosum of affected mice. It is 
unknown what induces macrophages to engulf sulfatide-enriched myelin. Sulfatides and 
gangliosides induce the release of a plethora of pro-inflammatory mediators from cultured 
primary microglia; a response that can be blunted by pretreating these cells with small 
interfering RNA against L-selectin (CD62L) or a TLR4 antagonist, respectively  
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(Jeon et al., 2008; Jou et al., 2006). These receptors could provide new targets for the 
development of therapeutic strategies (Figure 2). 
Conclusions 
Despite the fact that the CNS and the PNS are considered ‘immune privileged’ tissues with 
respect to the blood-brain and blood-nerve barriers’ restricted permeability, the nervous tissue 
is constantly kept under surveillance by infiltrating lymphocytes and resident 
microglia/macrophages. This is of vital importance because neural cells are host to infectious 
agents, and these are readily reactivated when immune surveillance fails. In addition to this 
defensive role, immune cells also fulfill housekeeping tasks such as in synapse remodeling 
and myelin turnover. In the white matter, inherited myelin defects are often associated with 
the abnormal activation of microglia/macrophages and occasionally a significant infiltration 
of clonally expanded lymphocytes (CD4+, CD8+ T cells). Studied in mouse models of PMD, 
adrenoleukodystrophy, myelin-associated lipid storage diseases (MLD), and various 
peripheral neuropathies (Charco-Marie-Tooth disease), these immune cells are observed in 
close proximity to sites of pathology (demyelination, axonopathy) and have been shown in 
some models to contribute to disease severity. In other models, however, such as in toxic 
myelin injury (cuprizone) and brain trauma (or nerve injury), immune cells contribute to a 
more efficient clearance of debris and thus improved remyelination and regeneration. Clinical 
applications of these observations will be possible only when independent assessments of the 
extent of neuroinflammation in the corresponding human leukodystrophies and peripheral 
neuropathies will be conducted, given the many differences of the immune responses 
emerging between mouse and human (Seok et al., 2013). Therefore, the outcome of a 
neuroinflammatory response is context specific. The specificity is determined by the ligands 
that glial cells present to resident cells of the immune system. Harnessing glial mediators for a 
supportive (rather than detrimental) immune response would be of a great benefit for 
leukodystrophy and neuropathy patients. This requires a better understanding of the complex 
array of neuroimmune activators that appears specific for each disease. 
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Tables and figures 
Table 1 Cause of demyelination associated with inflammation in human disorders 
affecting the nervous system. 
Cause of demyelination Examples of human disorders Rodent models 
Autoimmunity, including epitope mimicry 
and abnormal immune regulation 
- Multiple sclerosis (MS) 
- Guillain-Barré syndrome 
(GBS) 










Oligodendrocyte and Schwann cell death, 
caused by trauma, viral infection, apoptosis, 
necrosis 
- Brain and spinal cord injury 
- Ischemia 
- Progressive multifocal 
leukoencephalopathy (PML) 
- Nerve injury 
- Stab wound lesion 
 Contusion injury 
- Toxic injury (Cuprizone, 
Ethidium Bromide, 
Lysolecithin) 
- Middle cerebral artery 
occlusion (MCAO) 
- Theiler’s virus Mouse 
hepatitis virus  
- Sciatic nerve crush 
Genetic defects of oligodendrocytes and 
Schwann cells, including myelin gene 










- Corresponding mouse 
mutants: spontaneous or 
generated by gene 
targeting* 
*For details see text 
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Figure 1 Microglial activation and degenerating myelin disposal following cuprizone 
mediated oligodendroglial apoptosis. 
Dietry cuprizone induces the death of oligodendrocytes and cause compact myelin damage in 
addition to axonal transport blockage (spheroids). Apoptosis induces the translocaton of 
phosphatidylserine (PS) to the cell surface where it can bind Gas6. Meanwhile, heat-shock 
proteins (HSP) and adenosine triphosphate (ATP) released from dying oligodendrocytes, 
which are ligands of astrocytic Toll-like receptor (TLR) and purinergic 2X receptors (P2X), 
respectively, trigger the release of CXCL10. CXCL10 primes the microglia to start their 
myelin phagocytosis program. This occurs through Axl receptors which recognizes Gas6 and 
potentially by other receptors (Trem2b, CR3, SRA I/II). 
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Figure 2 Hypothetical molecular neuroimmune activation model in PMD/CMT and 
peroxisomal biogenesis/MLD diseases.  
A vicious cycle of demyelination is initiated and maintained by a primary myelinating cell 
defect, that subsequently activates microglia/macrophages and T cells. In PMD/CMT models 
(right part), aberrant myelin protein expression (PLP, MPZ) modifies the composition of lipid 
rafts and the exposure of the ganglioside sialic acid moiety (red triangle). These molecules 
react with the microglial sialoadhesin (Sn/CD169) receptor which mediate the myelin 
engulfment. Perturbed Schwann cells would reinforce these activation processes by MCP-1 
(dark blue asterisks) release, which binds its receptor (CCR2) on resident macrophages.  
T cells could perpetrate a second hit on defective myelin, promoting demyelination and 
secondary axonal injury. When peroxisome biogenesis is impaired (left part), altered myelin 
sheaths (light blue rectangles) owing to accumulation of VLCFA, are tagged by C1q 
molecules which act as ‘eat-me’ signals to trigger the microglial myelin debris (light blue half 
moon) detachment and phagocytosis via CR3 which can be supported by eicosanoides  
(e.g: leukotriene, dark blue asterisks acting on its receptor LTR). This leads also to the 
recruitment of T cells whose functions are not clear. In MLD, other lipophilic receptors  
(TLR, CD62L) can contribute to the same activation process. 
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